Abstract
ObjectiveThe management of systemic lupus erythematosus (SLE) flares can incur substantial healthcare costs. In the phase III BLISS-SC trial, subcutaneous (SC) belimumab 200 mg plus standard therapy was associated with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have